Ceftolozane/tazobactam
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Burns
Conditions
Burns, Pharmacokinetics
Trial Timeline
Aug 21, 2017 → Jun 30, 2020
NCT ID
NCT03002506About Ceftolozane/tazobactam
Ceftolozane/tazobactam is a approved stage product being developed by Merck for Burns. The current trial status is terminated. This product is registered under clinical trial identifier NCT03002506. Target conditions include Burns, Pharmacokinetics.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04223752 | Phase 1 | Completed |
| NCT03002506 | Approved | Terminated |
| NCT02620774 | Phase 1 | Completed |
| NCT02421120 | Approved | Completed |
Competing Products
12 competing products in Burns
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| R-Pdf/Gbb 0.01% gel | Johnson & Johnson | Phase 2 | 52 |
| linezolid | Pfizer | Phase 1 | 32 |
| Somatropin + 0.09% Saline Solution | Pfizer | Phase 2/3 | 64 |
| Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867) | Bayer | Phase 3 | 74 |
| cP12 | United Therapeutics | Phase 2 | 49 |
| cNP8 | United Therapeutics | Phase 1 | 30 |
| Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal Medications | Viatris | Approved | 82 |
| Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin | Baxter | Phase 1/2 | 38 |
| I-020502 | Baxter | Phase 2 | 49 |
| Pathogen-Reduced Plasma + Crystalloid Solutions | Cerus | Approved | 77 |
| NexoBrid + Gel Vehicle | MediWound | Phase 3 | 69 |
| NexoBrid | MediWound | Phase 3 | 69 |